epetraborole – Patient Worthy

pixabay.com

Epetraborole Granted Orphan Drug Designation for NTM Lung Disease

Post author:Jessica Lynn
Post published:February 17, 2022
Post category:Nontuberculous Mycobacteria (NTM) Lung Diseas Nontuberculous Mycobacteria Lung Disease

In a news release from February 16, 2022, clinical-stage biopharmaceutical company AN2 Therapeutics, Inc. ("AN2") shared that its therapy epetraborole was granted Orphan Drug designation for the treatment of non-tuberculous…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More